Tutorials › Pharmacometrics › Absolute vs. Relative Bioavailability
Pharmacokinetics · PK/PD Foundations

Absolute vs. Relative Bioavailability

Understand how absolute and relative bioavailability quantify systemic drug exposure, how AUC and dose normalization are used in their calculation, and how to interpret bioavailability comparisons in pharmacokinetic studies.

Beginner PK Fundamentals Bioavailability Clinical Pharmacology
01 · The big picture

1. What Is Bioavailability?

Bioavailability describes the rate and extent to which an administered drug reaches the systemic circulation. For many pharmacokinetic applications, the extent of systemic availability is quantified using the area under the concentration-time curve (AUC).

The concept becomes especially important when a drug is administered by a route other than intravenous administration. An IV dose is conventionally treated as having complete systemic availability, whereas an oral, intramuscular, subcutaneous, or other extravascular dose may undergo incomplete absorption and presystemic loss.

IV dose Systemic circulation AUC Oral dose absorption + presystemic loss AUC

Bioavailability compares systemic exposure following an administration route with an appropriate reference, usually using dose-normalized AUC.

Core idea: absolute bioavailability asks how much systemic exposure an extravascular route produces relative to IV administration, whereas relative bioavailability compares systemic exposure from one non-IV formulation or route with another.
02 · Absolute bioavailability

2. What Is Absolute Bioavailability?

Absolute bioavailability, commonly denoted by \(F\), compares systemic exposure after an extravascular dose with exposure after an IV dose of the same drug.

Because IV administration is generally treated as providing complete systemic availability, the IV route provides the reference against which the extravascular route is evaluated.

For linear PK and exposure measured by AUC:

\[ F=\frac{AUC_{\mathrm{EV}}/D_{\mathrm{EV}}}{AUC_{\mathrm{IV}}/D_{\mathrm{IV}}} \]

Equivalently:

\[ F=\frac{AUC_{\mathrm{EV}}\times D_{\mathrm{IV}}}{AUC_{\mathrm{IV}}\times D_{\mathrm{EV}}} \]

If the IV and extravascular doses are identical, the equation simplifies to:

\[ F=\frac{AUC_{\mathrm{EV}}}{AUC_{\mathrm{IV}}} \]

Bioavailability is often reported as a percentage:

\[ F(\%)=100\times F \]
Important: the dose-normalization term is essential when the IV and extravascular doses are different. Comparing raw AUC values without accounting for dose can produce an incorrect estimate of bioavailability.
03 · Interpreting F

3. What Does an Absolute Bioavailability of 60% Mean?

Suppose a drug has an estimated absolute bioavailability of \(F=0.60\), or 60%.

This means that, under the conditions of the study and the assumptions of the analysis, the systemic exposure produced per unit of administered dose by the extravascular route is approximately 60% of that produced by IV administration.

It does not necessarily mean that exactly 60% of the swallowed drug entered the body unchanged. Several processes can contribute to the difference between the administered dose and systemic availability.

Process Potential effect on systemic availability
Incomplete absorption Some of the administered dose may never reach the systemic circulation.
Gut-wall metabolism Drug can be metabolized before reaching systemic circulation.
Hepatic first-pass metabolism Drug entering the portal circulation may be metabolized before reaching systemic circulation.
Chemical or enzymatic degradation Drug may be lost before reaching the systemic circulation.
Formulation effects Release or dissolution characteristics can affect the amount and rate of drug becoming available.

Thus, systemic bioavailability reflects the combined result of processes occurring between administration and entry into the systemic circulation.

04 · The fundamental equation

4. Why Is AUC Used to Estimate Bioavailability?

For a linear PK system, systemic exposure following an IV dose is related to clearance:

\[ AUC_{\mathrm{IV},0-\infty}=\frac{D_{\mathrm{IV}}}{CL} \]

For an extravascular dose with bioavailability \(F\):

\[ AUC_{\mathrm{EV},0-\infty}=\frac{F D_{\mathrm{EV}}}{CL} \]

Taking the ratio gives:

\[ \frac{AUC_{\mathrm{EV}}}{AUC_{\mathrm{IV}}} = \frac{F D_{\mathrm{EV}}}{D_{\mathrm{IV}}} \]

Rearranging produces the dose-normalized bioavailability equation:

\[ F= \frac{AUC_{\mathrm{EV}}/D_{\mathrm{EV}}} {AUC_{\mathrm{IV}}/D_{\mathrm{IV}}} \]
Why this works: under linear PK, AUC is proportional to the amount of drug reaching the systemic circulation. Dividing AUC by dose removes the effect of different administered doses, allowing the systemic availability of the routes to be compared.
05 · Relative bioavailability

5. What Is Relative Bioavailability?

Relative bioavailability compares systemic exposure from one formulation or extravascular administration condition with exposure from another reference formulation or condition.

Unlike absolute bioavailability, relative bioavailability does not require an IV reference.

If a test formulation and reference formulation are administered at different doses:

\[ F_{\mathrm{rel}}= \frac{AUC_{\mathrm{Test}}/D_{\mathrm{Test}}} {AUC_{\mathrm{Reference}}/D_{\mathrm{Reference}}} \]

If the doses are identical:

\[ F_{\mathrm{rel}}= \frac{AUC_{\mathrm{Test}}}{AUC_{\mathrm{Reference}}} \]

Relative bioavailability is therefore useful when the primary question is whether two non-IV formulations or administration conditions produce different systemic exposure.

Feature Absolute bioavailability Relative bioavailability
Reference IV administration Another formulation or non-IV condition
Primary question How much systemic availability does the extravascular route provide relative to IV? How does systemic exposure from the test condition compare with the reference condition?
IV data required? Yes, for the standard direct estimate No
Typical metric Dose-normalized AUC ratio Dose-normalized AUC ratio
Common application Characterizing systemic availability of a route or formulation Comparing formulations, dosage forms, or administration conditions
06 · Worked example

6. Worked Example: Absolute Bioavailability

Suppose a drug is studied after a 100 mg IV dose and a 200 mg oral dose. The observed AUC values are:

Route Dose AUC0-∞
IV 100 mg 50 mg·h/L
Oral 200 mg 60 mg·h/L

Step 1: Normalize the IV exposure by dose

\[ \frac{AUC_{\mathrm{IV}}}{D_{\mathrm{IV}}} = \frac{50}{100} = 0.50 \]

Step 2: Normalize the oral exposure by dose

\[ \frac{AUC_{\mathrm{oral}}}{D_{\mathrm{oral}}} = \frac{60}{200} = 0.30 \]

Step 3: Calculate absolute bioavailability

\[ F= \frac{0.30}{0.50} = 0.60 \]

Step 4: Express as a percentage

\[ F(\%)=100(0.60)=60\% \]

The estimated absolute bioavailability is therefore 60%.

Interpretation: on a dose-normalized basis, the oral administration produced approximately 60% of the systemic exposure produced by IV administration. This is an exposure comparison, not a direct measurement of the percentage of molecules that physically crossed the intestinal wall.
07 · Worked example

7. Worked Example: Relative Bioavailability

Now suppose two oral formulations are compared in the same hypothetical drug:

Formulation Dose AUC0-∞
Test formulation 100 mg 42 mg·h/L
Reference formulation 100 mg 50 mg·h/L

Because the doses are identical, the dose terms cancel:

\[ F_{\mathrm{rel}} = \frac{42}{50} = 0.84 \]

Expressed as a percentage:

\[ F_{\mathrm{rel}}(\%)=84\% \]

The test formulation produced 84% of the dose-normalized systemic exposure of the reference formulation under the conditions of this study.

Notice that this calculation does not say that the test formulation has 84% absolute bioavailability. There is no IV reference in this comparison, so the result is a relative bioavailability measure.

08 · Rate vs. extent

8. Bioavailability Has Both Rate and Extent Components

Bioavailability is often discussed in terms of the extent of systemic availability, which is commonly quantified using AUC. The rate at which drug reaches the systemic circulation is described by other PK measures.

For an extravascular dose, common measures include:

Measure What it describes
AUC Overall systemic exposure and, under appropriate linear PK assumptions, the extent of systemic availability.
Cmax The maximum observed concentration.
Tmax The time at which the maximum observed concentration occurs.
Absorption rate How rapidly drug enters the systemic circulation according to the applicable PK model.

Two formulations can therefore have similar AUC values but noticeably different concentration-time profiles. In such a situation, the extent of exposure may be similar even though the rate of absorption differs.

Key distinction: AUC primarily informs the extent of systemic exposure, while Cmax, Tmax, and absorption parameters provide information about the rate and timing of exposure.
09 · Why IV is the reference

9. Why Is IV Administration Used as the Reference?

Intravenous administration is useful as the reference because drug is delivered directly into the systemic circulation. Under the conventional definition, an IV dose has a bioavailability of 1, or 100%.

This makes the IV exposure a benchmark for determining how much exposure is obtained through another route.

For a linear system:

\[ AUC_{\mathrm{IV}}=\frac{D_{\mathrm{IV}}}{CL} \]

For an extravascular route:

\[ AUC_{\mathrm{EV}}=\frac{F D_{\mathrm{EV}}}{CL} \]

The same systemic clearance appears in both expressions. Taking the dose-normalized ratio therefore isolates \(F\), provided the assumptions required for the comparison are reasonable.

10 · First-pass effects

10. First-Pass Metabolism and Bioavailability

For an orally administered drug, systemic availability can be reduced by both incomplete absorption and presystemic metabolism.

A conceptual decomposition is:

\[ F \approx F_a \times F_g \times F_h \]

where:

  • \(F_a\) represents the fraction of the administered dose that is absorbed.
  • \(F_g\) represents the fraction escaping intestinal loss or gut-wall metabolism.
  • \(F_h\) represents the fraction escaping hepatic first-pass extraction.

This decomposition is a useful conceptual framework in pharmacokinetics, although the exact interpretation and identifiability of individual components depend on the study design and available data.

For example, a drug can be well absorbed from the gastrointestinal tract but still have low oral bioavailability if substantial presystemic metabolism occurs.

Important: low oral bioavailability does not automatically imply poor intestinal absorption. A drug may be absorbed efficiently but undergo substantial presystemic elimination before reaching systemic circulation.
11 · Dose normalization

11. Why Dose Normalization Matters

Imagine that a 100 mg IV dose produces an AUC of 50 mg·h/L while a 200 mg oral dose produces an AUC of 60 mg·h/L.

It would be incorrect to conclude that oral bioavailability is:

\[ \frac{60}{50}=120\% \]

The oral dose was twice as large. The appropriate comparison is based on AUC per unit dose:

\[ F= \frac{60/200}{50/100} = 0.60 \]

Therefore, the estimated absolute bioavailability is 60%, not 120%.

Practical rule: whenever doses differ, normalize exposure by dose before calculating an absolute or relative bioavailability ratio.
12 · Linearity matters

12. What If PK Is Nonlinear?

The standard AUC-ratio approach relies on assumptions that are particularly straightforward under linear PK.

In a linear system, doubling the dose is expected to produce approximately twice the AUC, all else being equal. This proportionality makes dose normalization meaningful.

With nonlinear pharmacokinetics, clearance, absorption, metabolism, or other processes may change with dose. In that setting, AUC may not increase proportionally with dose.

Situation Interpretation
Linear PK Dose-normalized AUC comparisons are generally straightforward.
Nonlinear PK AUC may not be proportional to dose, so a single bioavailability estimate may not adequately characterize the relationship across doses.
Dose-dependent absorption The fraction absorbed may change with dose.
Saturable first-pass metabolism Systemic availability can change with dose.
Saturable elimination AUC may increase more or less than proportionally with dose, complicating interpretation.

Consequently, bioavailability studies should consider whether the dose range and observed PK support the assumptions behind dose-normalized comparisons.

13 · AUC selection

13. AUC0-t vs. AUC0-∞

Bioavailability calculations can involve AUC measured to the last quantifiable concentration, \(AUC_{0-t}\), or AUC extrapolated to infinity, \(AUC_{0-\infty}\).

The choice depends on the study design, sampling duration, data quality, and purpose of the analysis.

Measure Definition Consideration
AUC0-t Exposure from time zero through the last relevant observation time. Relies primarily on observed data within the sampling interval.
AUC0-∞ Exposure from time zero extrapolated to infinite time. Includes an extrapolated terminal component and therefore depends on adequate characterization of the terminal phase.

For AUC extrapolated to infinity, the terminal contribution is commonly represented as:

\[ AUC_{t-\infty}=\frac{C_t}{\lambda_z} \]

where \(C_t\) is the final concentration used for extrapolation and \(\lambda_z\) is the terminal elimination rate constant under the applicable analysis.

Interpretation caution: a large fraction of AUC coming from extrapolation can make an \(AUC_{0-\infty}\)-based comparison more sensitive to uncertainty in the terminal phase.
14 · Study design

14. Designing a Bioavailability Study

A useful bioavailability study must collect sufficient information to estimate exposure accurately for the test and reference conditions.

  1. Select the reference condition. For absolute bioavailability, this generally involves an IV administration; for relative bioavailability, it is another appropriate formulation or route.
  2. Choose appropriate doses. Dose selection should support interpretable exposure comparisons and respect safety constraints.
  3. Plan the sampling schedule. Samples should characterize the absorption phase, peak concentration, and relevant elimination phase.
  4. Measure concentrations accurately. Analytical performance affects the resulting concentration-time profile and AUC.
  5. Calculate exposure. AUC can be estimated using an appropriate PK analysis method.
  6. Normalize for dose. This is particularly important when the administered doses differ.
  7. Compare the conditions. Calculate the appropriate exposure ratio and quantify uncertainty where required.

Study design is especially important for \(AUC_{0-\infty}\), because the sampling schedule must adequately characterize the terminal disposition phase.

15 · Interpretation

15. Similar AUC Does Not Mean Identical Profiles

Consider two oral formulations with the same dose and similar AUC values. One formulation produces a rapid rise and early peak, while the other produces a slower rise and later peak.

The formulations could have similar overall exposure but different rates of absorption.

Faster absorption Slower absorption 0 Time C

Different absorption rates can produce different Cmax and Tmax values even when total exposure, represented by AUC, is similar.

This distinction is central to interpreting bioavailability data. AUC primarily addresses the extent of systemic exposure, whereas Cmax, Tmax, and absorption-rate characteristics provide additional information about how rapidly exposure occurs.

16 · Applications

16. When Is Relative Bioavailability Useful?

Relative bioavailability is useful whenever the scientific question concerns exposure differences between two non-IV conditions.

  • Comparing an experimental formulation with an existing formulation.
  • Evaluating changes in formulation composition.
  • Comparing different dosage forms.
  • Assessing the effect of food or other administration conditions when an appropriate reference is defined.
  • Comparing different manufacturing formulations during development.
  • Evaluating changes in formulation or administration that could alter systemic exposure.

The interpretation should always identify exactly what the reference condition was. A relative bioavailability value is meaningful only with respect to the particular test and reference conditions that generated it.

17 · Related concept

17. Bioavailability vs. Bioequivalence

Bioavailability and bioequivalence are related but distinct concepts.

A bioavailability study may quantify exposure after a particular formulation or route. A bioequivalence study asks whether the exposure from a test product is sufficiently comparable with that from a reference product according to a prespecified statistical framework and regulatory criteria.

Concept Primary purpose
Absolute bioavailability Quantify systemic availability relative to IV administration.
Relative bioavailability Compare systemic exposure between a test and reference non-IV condition.
Bioequivalence Evaluate whether two products meet prespecified criteria for comparable exposure under a defined study and statistical framework.

Thus, a relative bioavailability calculation is not by itself a complete bioequivalence analysis.

18 · Common mistakes

18. Common Mistakes When Calculating Bioavailability

1. Comparing raw AUC values when doses differ

Always consider dose normalization when the administered doses are not identical.

2. Calling every AUC ratio absolute bioavailability

An AUC ratio between two oral formulations is generally a relative bioavailability comparison. Absolute bioavailability requires an appropriate IV reference for the standard direct estimate.

3. Treating \(F\) as a direct measurement of absorption

Systemic bioavailability can be affected by incomplete absorption, intestinal metabolism, hepatic first-pass metabolism, and other presystemic processes.

4. Ignoring nonlinear PK

Dose-normalized comparisons are most straightforward when the PK is sufficiently linear over the doses being compared.

5. Ignoring the terminal phase

If \(AUC_{0-\infty}\) is used, inadequate characterization of the terminal phase can increase uncertainty in the extrapolated exposure.

6. Assuming similar AUC means identical drug behavior

Two formulations can have similar AUC but different Cmax, Tmax, and absorption profiles.

Best practice: interpret bioavailability using the full concentration-time profile, not AUC alone. AUC answers an important exposure question, but it does not describe every feature of drug absorption and disposition.
19 · Practical workflow

19. A Practical Bioavailability Analysis Workflow

  1. Define the scientific question. Are you estimating absolute bioavailability or comparing two non-IV conditions?
  2. Identify the reference. Determine whether the reference is IV or another formulation/route.
  3. Confirm the doses. Record the administered dose for each condition.
  4. Inspect concentration-time profiles. Verify that the sampling schedule captures the relevant absorption and elimination phases.
  5. Calculate AUC. Use an appropriate method and clearly define the AUC interval.
  6. Normalize AUC by dose. Do this whenever the doses differ.
  7. Calculate the exposure ratio. Use the appropriate absolute or relative bioavailability equation.
  8. Evaluate assumptions. Consider linearity, terminal-phase characterization, and potential formulation or study-condition effects.
  9. Interpret rate and extent separately. Consider AUC alongside Cmax, Tmax, and other relevant PK measures.
  10. Quantify uncertainty. For inferential comparisons, use an appropriate statistical framework rather than relying only on the point estimate.

20. Key Takeaways

  • Bioavailability describes the rate and extent to which an administered drug reaches the systemic circulation.
  • Absolute bioavailability compares dose-normalized systemic exposure after an extravascular administration with exposure after IV administration.
  • The standard absolute bioavailability equation is \[ F=\frac{AUC_{\mathrm{EV}}/D_{\mathrm{EV}}}{AUC_{\mathrm{IV}}/D_{\mathrm{IV}}}. \]
  • Relative bioavailability compares dose-normalized exposure from a test formulation or condition with an appropriate non-IV reference.
  • When doses are identical, the dose terms cancel and the bioavailability calculation becomes a simple AUC ratio.
  • AUC primarily provides information about the extent of systemic exposure, whereas Cmax and Tmax provide information about the rate and timing of exposure.
  • An absolute bioavailability of 60% does not necessarily mean that exactly 60% of the administered drug was absorbed; presystemic loss can occur through several mechanisms.
  • Dose normalization is essential when the test and reference doses differ.
  • The standard AUC-ratio approach is most straightforward under approximately linear PK.
  • AUC0-∞ depends partly on characterization of the terminal phase, so extrapolation should be considered when interpreting exposure estimates.
  • Relative bioavailability is not synonymous with bioequivalence; bioequivalence involves a separate prespecified statistical and regulatory framework.
  • The most informative interpretation considers AUC together with the full concentration-time profile and the assumptions underlying the analysis.
Next step

Where to Go Next

A natural next topic is Bioavailability and Bioequivalence Fundamentals, which builds on the distinction between absolute and relative bioavailability and introduces the statistical concepts used to compare pharmacokinetic exposure between formulations.

From there, useful extensions include AUC calculation and interpretation, Cmax and Tmax, first-pass metabolism, noncompartmental analysis, and the statistical analysis of bioequivalence studies.

References

References

  1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Wolters Kluwer.
  2. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker.
  3. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. McGraw Hill.
  4. FDA. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations.

Bioavailability calculations should be interpreted in the context of the study design, dose, route of administration, sampling schedule, analytical method, and assumptions underlying the PK analysis.

Related Tutorials

Clinical Biostats

← Back to Pharmacokinetics Tutorials